Cytokinetics Forecasts Q4 EPS of -$1.48 on $8.02M Revenue
Cytokinetics is forecast to post Q4 EPS of -$1.48 and revenue of $8.02 million, signaling ongoing losses with a negative P/E of -10.86 and price-to-sales ratio of 95.39. The company’s strong current ratio of 6.88 contrasts with an EV/operating cash flow multiple of -21.46 and a debt-to-equity ratio of -2.30.
1. Q4 Earnings Estimates
Cytokinetics projects Q4 EPS of -$1.48 and revenue of $8.02 million, matching consensus estimates and underscoring ongoing operational losses.
2. Premium Valuation Metrics
The company’s negative P/E ratio of -10.86 coupled with a price-to-sales ratio of 95.39 and an EV/Sales ratio of 106.53 reflects high valuation multiples despite unprofitability.
3. Liquidity and Cash Flow Challenges
Liquidity metrics show a current ratio of 6.88, indicating ample short-term coverage, but an EV/operating cash flow multiple of -21.46 and a debt-to-equity ratio of -2.30 highlight challenges in generating positive cash flow and elevated liabilities.
4. Upcoming Earnings Call
The Q4 earnings call is scheduled for 4:30 PM ET on February 24, where management will discuss financial results, cash flow outlook, and strategic priorities for 2026.